Furthermore, the KEYNOTE-224 and CheckMate-040 trials demonstrated the safety and efficacy of PD-1 inhibitors in HCC without exacerbation of HCV flares [13,30]. Here, PDCD1 is linked to hepatocellular carcinoma.